

Angola

Support for Vaccine: Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme

-
1. **Country:** Angola
-
2. **Vaccine grant number:** AGO-IPV-R
-
3. **Date of Decision Letter:** 28 September 2020
-
4. **Date of the Partnership Framework Agreement:** 04 October 2013
-
5. **Programme title:** New Vaccine Support (NVS), Inactivated Polio Vaccine (IPV), Routine, 1 dose
-
6. **Vaccine type:** Inactivated Polio Vaccine (IPV)
-
7. **Requested product presentation and formulation of vaccine:**
IPV, 10 doses/vial, liquid
-
8. **Programme duration:**¹ 2015-2021
-
9. **Programme Budget (indicative):**²³ (subject to the terms of the Partnership Framework Agreement, if applicable)

	2015-2020	2021	2022	2023	2024	2025	Total ²
Programme Budget (US\$)	5.880.122	3.880.543	-	-	-	-	9.760.665

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³ This is the amount that Gavi has approved.

10. Vaccine introduction grant:

Approval		
Year	Grant number	Amount (US\$)
2015	AGO-IPV-R-VIG-WHO	785.500

11. Product switch grant:

Not applicable

12. Indicative annual amounts:³

(subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2015-2020	2021	2022
Number of vaccine doses	-	1.842.000	-
Number of AD syringes	-	1.417.800	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	15.600	-
Annual Amounts (US\$)	5.880.122	3.880.543	-

13. Procurement agency: UNICEF Supply Division

14. Self-procurement:

Not applicable

15. Co-financing obligations:

Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

Reports and other information:	Due dates
--------------------------------	-----------

<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> • vaccine stock levels including buffer stock, by end of March; • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. • Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 15 May</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

18. Financial clarifications:

Not applicable


19. Other conditions:

Insurance:

According to Gavi's Grant Management Requirements (GMR), the Ministry of Health will be responsible for all program assets, including vaccines and related supplies, cold chain equipment and other tangible assets (to be procured through UN agencies) at both central and regional levels depending on the size of the program and availability of the budget. If possible and at reasonable cost, the Ministry of Health will have to take out all-risk insurance and general liability insurance with reputable and strong insurance companies by choosing a cover corresponding to the policies held by similar organizations that carry out comparable activities. otherwise the Ministry of Health will have to provide a budget line to supply the replacement of damaged or missing vaccines or assets.

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,
On behalf of Gavi



Pascal Bijleveld
Director, Country Support

Date: 28 September 2020